Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation

Abstract

Patients with CNV who develop tachyphylaxis to ranibizumab or bevacizumab may respond to another anti-VEGF drug. The majority of cases (81%) in this series demonstrated at least some response after switching therapies.